Novo Nordisk makes $1.1bn bid for biopharma company

Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Big pharma co buys $16.6bn for heart tech company

2 November 2022 Cardiovascular ‘innovator’ snapped up as company strengthens medtech offering | Massachusetts-based Abiomed will become part of purchaser’s medtech division

Americas

Pfizer bolsters haematology expertise with $5.4bn deal

9 August 2022 Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.

Generics

Novo Nordisk and Sandoz settle Victoza patent suit

24 March 2022 Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza before the companies were meant to face trial in April.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Novo Nordisk makes $1.1bn bid for biopharma company

More on this story

Editor's picks

Editor's picks

More features